食品和药物管理局批准Zepbound, 这是治疗肥胖成年人睡眠性脑膜炎的第一种减重药物。 The FDA approves Zepbound, the first weight-loss drug to treat sleep apnea in obese adults.

林业发展局批准了Zepbound,一种减重药物,作为在肥胖成人中治疗中度至严重阻塞性睡眠apnea的首例药物。 The FDA has approved Zepbound, a weight-loss drug, as the first medication to treat moderate to severe obstructive sleep apnea in adults with obesity. 研究表明,Zepbound减少呼吸中断,导致体重大幅下降,改善睡眠性脑膜症状。 Studies show that Zepbound reduces breathing interruptions and leads to significant weight loss, improving sleep apnea symptoms. 这项批准可以增加该药物的保险范围,使估计有8 000万未诊断为OSA的美国成年人受益。 The approval could increase insurance coverage for the drug, benefiting the estimated 80 million U.S. adults with undiagnosed OSA.